IBSA: STRATEGIC LICENSING AND CDMO PROJECTS FOR THE PHARMACEUTICAL MARKET
IBSA will once again be back at CphI Worldwide 2022, Frankfurt, 1-3 November, to present its innovative solutions for the pharmaceutical market, developed in cutting-edge R&D centers and realized in state-of-the art technology production sites.Read the Whole Interview
CPHI April 19-21 TOKYO: IBSA returns to Japan after the pandemic.
IBSA operates in more than 90 countries and 5 continents with 17 subsidiaries in Europe, China and the USA, and employs over 2,000 collaborators distributed among our headquarters, subsidiaries and manufacturing plants. The Group boasts an extensive product portfolio that includes different therapeutic categories, such as prescription drugs, OTC medicines, medical devices and food supplements, and covers 10 therapeutic areas.Read more
DELIVERING INNOVATIVE SOLUTIONS FOR THE NUTRACEUTICAL MARKET
IBSA was established in Lugano in 1945 and started developing its special identity in 1985 when it was acquired by the current ownership, which adopted a new strategy focused on the acquisition of technological resources and launched a development programme aimed at consolidating its global expansion and developing company assets. Today IBSA is present in over 90 countries in 5Read more